Midlife body mass index may play important role in modifying this risk
FRIDAY, July 31, 2020 (HealthDay News) — Early age at menarche is a risk factor for menopausal symptoms, according to a study published online July 21 in BJOG: An International Journal of Obstetrics & Gynaecology.
Hsin-Fang Chung, Ph.D., from the University of Queensland in Brisbane, Australia, and colleagues evaluated the association between age at menarche and risk for vasomotor menopausal symptoms (VMS; hot flushes and night sweats) and the impact of midlife body mass index (BMI). The analysis included 18,555 women from the United Kingdom, United States, and Australia pooled from six cohort studies.
The researchers found that early menarche (≤11 years) was associated with an increased risk for “often” hot flushes (relative risk ratio [RRR], 1.48; 95 percent confidence interval [CI], 1.24 to 1.76) and night sweats (RRR, 1.59; 95 percent CI, 1.49 to 1.70) versus menarche at ≥14 years. Similar trends were seen with severity data but appeared less conclusive (RRR for “severe” hot flushes: 1.16 [95 percent CI, 0.94 to 1.42]; RRR for night sweats: 1.27 [95 percent CI, 1.01 to 1.58]). The risk associated with early menarche and “often” VMS was stronger among women who were overweight or obese versus normal weight, but this trend across BMI categories was not as strong with the risk for “severe” VMS.
“These findings encourage women with early menstruation to engage in health promotion programs, especially weight management in adulthood,” a coauthor said in a statement.
Abstract/Full Text (subscription or payment may be required)
Estrogen Hormone Treatment May Be Beneficial for Brain Fog Symptoms in Menopausal Women
Model May Help Identify Women at Risk for Overactive Bladder
Menopausal Hormone Therapy Use Linked to Lower Risk for Alzheimer Disease
AMH Predicts Benefit of Chemo + Endocrine Therapy in Under 55s With Breast Cancer
Chemo-Free Combo of Four Targeted Therapies Shows Promise in Metastatic Breast Cancer
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors
Dexrazoxane Offers Lasting Doxorubicin Cardioprotective Effect in Childhood Cancer Survivors
Study IDs Gaps in Hereditary Breast Cancer Risk Assessment Before Gender-Affirming Mastectomy